JP2007504241A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007504241A5 JP2007504241A5 JP2006525449A JP2006525449A JP2007504241A5 JP 2007504241 A5 JP2007504241 A5 JP 2007504241A5 JP 2006525449 A JP2006525449 A JP 2006525449A JP 2006525449 A JP2006525449 A JP 2006525449A JP 2007504241 A5 JP2007504241 A5 JP 2007504241A5
- Authority
- JP
- Japan
- Prior art keywords
- heteroaryl
- aryl
- heterocyclyl
- alkyl
- arylalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000623 heterocyclic group Chemical group 0.000 claims 135
- 125000001072 heteroaryl group Chemical group 0.000 claims 117
- 125000000217 alkyl group Chemical group 0.000 claims 104
- 125000003118 aryl group Chemical group 0.000 claims 102
- 125000003710 aryl alkyl group Chemical group 0.000 claims 87
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 65
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 57
- 150000001875 compounds Chemical class 0.000 claims 56
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 52
- 125000000753 cycloalkyl group Chemical group 0.000 claims 48
- 125000003342 alkenyl group Chemical group 0.000 claims 42
- 125000004093 cyano group Chemical group *C#N 0.000 claims 40
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims 40
- 125000005843 halogen group Chemical group 0.000 claims 40
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 40
- BPXYEYJNCXITEY-UHFFFAOYSA-N diazonio(trifluoromethoxy)azanide Chemical compound FC(F)(F)ON=[N+]=[N-] BPXYEYJNCXITEY-UHFFFAOYSA-N 0.000 claims 37
- 229910052739 hydrogen Inorganic materials 0.000 claims 28
- 125000000304 alkynyl group Chemical group 0.000 claims 24
- 239000001257 hydrogen Substances 0.000 claims 24
- 150000002431 hydrogen Chemical class 0.000 claims 21
- 229920006395 saturated elastomer Polymers 0.000 claims 20
- 125000004043 oxo group Chemical group O=* 0.000 claims 18
- 125000004429 atom Chemical group 0.000 claims 16
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 14
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 12
- 125000005865 C2-C10alkynyl group Chemical group 0.000 claims 12
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 12
- 239000000651 prodrug Substances 0.000 claims 12
- 229940002612 prodrug Drugs 0.000 claims 12
- 125000002837 carbocyclic group Chemical group 0.000 claims 10
- 125000000539 amino acid group Chemical group 0.000 claims 8
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 6
- -1 carbocycle Chemical group 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 6
- 239000012453 solvate Substances 0.000 claims 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 3
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000003463 hyperproliferative effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 0 Cc1n[o]c2c1cc(C(O)=*)c(Nc(c(Cl)c1)ccc1Cl)c2F Chemical compound Cc1n[o]c2c1cc(C(O)=*)c(Nc(c(Cl)c1)ccc1Cl)c2F 0.000 description 3
- QPUQVLGZNFJHCD-UHFFFAOYSA-N Cc1c(cc(C(O)=O)c(Nc2ccccc2Cl)c2F)c2n[o]1 Chemical compound Cc1c(cc(C(O)=O)c(Nc2ccccc2Cl)c2F)c2n[o]1 QPUQVLGZNFJHCD-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/654,580 US7144907B2 (en) | 2003-09-03 | 2003-09-03 | Heterocyclic inhibitors of MEK and methods of use thereof |
| US10/929,295 US7230099B2 (en) | 2003-09-03 | 2004-08-30 | Heterocyclic inhibitors of MEK and methods of use thereof |
| PCT/US2004/028649 WO2005023759A2 (en) | 2003-09-03 | 2004-09-01 | Heterocyclic inhibitors of mek and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007504241A JP2007504241A (ja) | 2007-03-01 |
| JP2007504241A5 true JP2007504241A5 (OSRAM) | 2007-07-12 |
| JP4131741B2 JP4131741B2 (ja) | 2008-08-13 |
Family
ID=34218110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006525449A Expired - Fee Related JP4131741B2 (ja) | 2003-09-03 | 2004-09-01 | 複素環式ｍｅｋ阻害剤、及びその使用方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US7144907B2 (OSRAM) |
| EP (1) | EP1673339B1 (OSRAM) |
| JP (1) | JP4131741B2 (OSRAM) |
| KR (1) | KR20060070558A (OSRAM) |
| CN (1) | CN1874769A (OSRAM) |
| AR (1) | AR046081A1 (OSRAM) |
| AU (1) | AU2004270699B2 (OSRAM) |
| BR (1) | BRPI0414111A (OSRAM) |
| CA (1) | CA2537321A1 (OSRAM) |
| IL (4) | IL173936A (OSRAM) |
| IS (1) | IS8392A (OSRAM) |
| MX (1) | MXPA06002466A (OSRAM) |
| NO (1) | NO20061506L (OSRAM) |
| PT (1) | PT1673339E (OSRAM) |
| RU (1) | RU2006109599A (OSRAM) |
| TW (1) | TW200526607A (OSRAM) |
| WO (1) | WO2005023759A2 (OSRAM) |
| ZA (1) | ZA200602581B (OSRAM) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7488823B2 (en) * | 2003-11-10 | 2009-02-10 | Array Biopharma, Inc. | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors |
| US7538120B2 (en) * | 2003-09-03 | 2009-05-26 | Array Biopharma Inc. | Method of treating inflammatory diseases |
| US7144907B2 (en) * | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| WO2005028426A1 (ja) * | 2003-09-19 | 2005-03-31 | Chugai Seiyaku Kabushiki Kaisha | 新規４−フェニルアミノ−ベンズアルドオキシム誘導体並びにそのmek阻害剤としての使用 |
| US7517994B2 (en) * | 2003-11-19 | 2009-04-14 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| JP4869075B2 (ja) * | 2003-11-19 | 2012-02-01 | アレイ バイオファーマ、インコーポレイテッド | Ｍｅｋの複素環阻害剤及びその使用方法 |
| MY144232A (en) | 2004-07-26 | 2011-08-15 | Chugai Pharmaceutical Co Ltd | 5-substituted-2-phenylamino benzamides as mek inhibitors |
| ATE443063T1 (de) * | 2004-12-01 | 2009-10-15 | Merck Serono Sa | Ä1,2,4ütriazoloä4,3-aüpyridin-derivative zur behandlung hyperproliferativer erkrankungen |
| CN101218238B (zh) * | 2005-03-21 | 2011-10-26 | S*Bio私人有限公司 | 咪唑并[1,2-a]吡啶衍生物：制备及药学应用 |
| US7666880B2 (en) * | 2005-03-21 | 2010-02-23 | S*Bio Pte Ltd. | Imidazo[1,2-A]pyridine derivatives: preparation and pharmaceutical applications |
| RU2500673C2 (ru) * | 2005-05-18 | 2013-12-10 | Астразенека Аб | Гетероциклические ингибиторы мек и способы их применения |
| KR20080087070A (ko) * | 2005-05-20 | 2008-09-30 | 알란토스 파마슈티컬즈 홀딩, 인코포레이티드 | 피리미딘 또는 트리아진 융합된 비시클릭 메탈로프로테아제억제제 |
| US20070155738A1 (en) | 2005-05-20 | 2007-07-05 | Alantos Pharmaceuticals, Inc. | Heterobicyclic metalloprotease inhibitors |
| US7572807B2 (en) * | 2005-06-09 | 2009-08-11 | Bristol-Myers Squibb Company | Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors |
| US7579360B2 (en) * | 2005-06-09 | 2009-08-25 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
| US8101799B2 (en) * | 2005-07-21 | 2012-01-24 | Ardea Biosciences | Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK |
| WO2007025090A2 (en) * | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase |
| AU2013203939B2 (en) * | 2005-10-07 | 2015-08-13 | Exelixis, Inc. | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
| EP1934174B1 (en) * | 2005-10-07 | 2011-04-06 | Exelixis, Inc. | Azetidines as mek inhibitors for the treatment of proliferative diseases |
| AU2012261703B2 (en) * | 2005-10-07 | 2015-08-13 | Exelixis, Inc. | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
| GB0601962D0 (en) | 2006-01-31 | 2006-03-15 | Ucb Sa | Therapeutic agents |
| GB0616214D0 (en) * | 2006-08-15 | 2006-09-27 | Ucb Sa | Therapeutic Agents |
| RU2444524C2 (ru) * | 2006-08-21 | 2012-03-10 | Дженентек, Инк. | Азабензотиофенильные соединения и способы применения |
| CA2660963A1 (en) * | 2006-08-21 | 2008-02-28 | Genentech, Inc. | Aza-benzothiophenyl compounds and methods of use |
| WO2008024725A1 (en) * | 2006-08-21 | 2008-02-28 | Genentech, Inc. | Aza-benzofuranyl compounds and methods of use |
| US7563797B2 (en) | 2006-08-28 | 2009-07-21 | Forest Laboratories Holding Limited | Substituted imidazo(1,2-A)pyrimidines and imidazo(1,2-A) pyridines as cannabinoid receptor ligands |
| JP5159630B2 (ja) * | 2006-09-13 | 2013-03-06 | 協和発酵キリン株式会社 | 縮環複素環誘導体 |
| KR20090094336A (ko) * | 2006-11-27 | 2009-09-04 | 하. 룬트벡 아크티에 셀스카브 | 헤테로아릴 아미드 유도체 |
| JP5311673B2 (ja) * | 2006-12-14 | 2013-10-09 | エグゼリクシス， インコーポレイテッド | Ｍｅｋ阻害剤の使用方法 |
| CA2682925A1 (en) * | 2007-04-10 | 2008-10-16 | David C. Ihle | Heteroaryl amide analogues |
| EP2181105B1 (en) | 2007-06-25 | 2015-04-29 | Novartis AG | N5-(2-ethoxyethyl)-n3-(2-pyridinyl)-3,5-piperidinedicarboxamide derivatives for use as renin inhibitors |
| GB0714384D0 (en) | 2007-07-23 | 2007-09-05 | Ucb Pharma Sa | theraputic agents |
| US8119658B2 (en) | 2007-10-01 | 2012-02-21 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
| WO2009064675A1 (en) * | 2007-11-12 | 2009-05-22 | Takeda Pharmaceutical Company Limited | Mapk/erk kinase inhibitors |
| PL2222675T3 (pl) * | 2007-12-19 | 2014-02-28 | Genentech Inc | 5-anilinoimidazopirydyny i sposoby zastosowania |
| CA2704125A1 (en) * | 2007-12-19 | 2009-07-09 | Genentech, Inc. | 8-anilinoimidazopyridines and their use as anti-cancer and/or anti-inflammatory agents |
| EP2240494B1 (en) | 2008-01-21 | 2016-03-30 | UCB Biopharma SPRL | Thieno-pyridine derivatives as mek inhibitors |
| GB0811304D0 (en) | 2008-06-19 | 2008-07-30 | Ucb Pharma Sa | Therapeutic agents |
| US8492427B2 (en) * | 2008-07-01 | 2013-07-23 | Genentech, Inc. | Isoindolones derivatives as MEK kinase inhibitors and methods of use |
| US8841462B2 (en) * | 2008-07-01 | 2014-09-23 | Robert A. Heald | Bicyclic heterocycles as MEK kinase inhibitors |
| MX2011006094A (es) | 2008-12-08 | 2011-11-29 | Gilead Connecticut Inc | Inhibidores de imidazopirazina syk. |
| WO2010068738A1 (en) | 2008-12-10 | 2010-06-17 | Dana-Farber Cancer Institute, Inc. | Mek mutations conferring resistance to mek inhibitors |
| PE20121816A1 (es) * | 2009-10-12 | 2013-01-02 | Hoffmann La Roche | Combinaciones de un inhibidor de pi3k y un inhibidor de mek |
| WO2011106298A1 (en) | 2010-02-25 | 2011-09-01 | Dana-Farber Cancer Institute, Inc. | Braf mutations conferring resistance to braf inhibitors |
| AU2011224410B2 (en) | 2010-03-09 | 2015-05-28 | Dana-Farber Cancer Institute, Inc. | Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy |
| BR112012022943A2 (pt) | 2010-03-11 | 2018-06-05 | Gilead Connecticut Inc | inibidores de syk de imidazopiridnas |
| EP2655362A1 (en) | 2010-12-22 | 2013-10-30 | Abbvie Inc. | Hepatitis c inhibitors and uses thereof |
| UY34305A (es) | 2011-09-01 | 2013-04-30 | Novartis Ag | Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar |
| EP2578582A1 (en) | 2011-10-03 | 2013-04-10 | Respivert Limited | 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors |
| CN103204827B (zh) | 2012-01-17 | 2014-12-03 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的苯并噻二唑化合物及其制备方法和用途 |
| EP2833889B1 (en) | 2012-04-04 | 2017-11-01 | Rigel Pharmaceuticals, Inc. | Protein kinase c inhibitors and uses thereof |
| US20150141470A1 (en) | 2012-05-08 | 2015-05-21 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
| CA2874905A1 (en) | 2012-05-31 | 2013-12-05 | Bayer Pharma Aktiengesellschaft | Biomarkers for determining effective response of treatments of hepatocellular carcinoma (hcc) patients |
| KR20240146112A (ko) | 2012-08-17 | 2024-10-07 | 에프. 호프만-라 로슈 아게 | 코비메티닙 및 베무라피닙을 투여함을 포함하는 흑색종의 조합 치료법 |
| HRP20180670T1 (hr) | 2012-10-12 | 2018-07-13 | Exelixis Inc. | Novi postupak dobivanja spojeva namijenjenih upotrebi u liječenju raka |
| UA111925C2 (uk) | 2012-12-11 | 2016-06-24 | Федора Фармасьютікалз Інк. | БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ |
| US9073921B2 (en) | 2013-03-01 | 2015-07-07 | Novartis Ag | Salt forms of bicyclic heterocyclic derivatives |
| EP2970275B1 (en) | 2013-03-14 | 2018-05-09 | Rigel Pharmaceuticals, Inc. | Protein kinase c inhibitors and uses thereof |
| PT2976106T (pt) | 2013-03-21 | 2021-05-26 | Array Biopharma Inc | Terapia de combinação que compreende um inibidor de b-raf e um segundo inibidor |
| EP3094736A4 (en) | 2014-01-14 | 2017-10-25 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms |
| CN103980217B (zh) * | 2014-05-26 | 2015-12-30 | 南京林业大学 | 一类蒎烷基异噁唑类化合物及其合成方法和应用 |
| AU2015328411C1 (en) | 2014-10-06 | 2022-03-03 | Dana-Farber Cancer Institute, Inc. | Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response |
| MA41866A (fr) | 2015-03-31 | 2018-02-06 | Massachusetts Gen Hospital | Molécules à auto-assemblage pour l'administration ciblée de médicaments |
| WO2017033113A1 (en) | 2015-08-21 | 2017-03-02 | Acerta Pharma B.V. | Therapeutic combinations of a mek inhibitor and a btk inhibitor |
| RU2638155C1 (ru) * | 2016-02-29 | 2017-12-12 | Общество С Ограниченной Ответственностью "Сай Фарма" | Производные бензо[d]изоксазола и их применение |
| CN107759532B (zh) * | 2017-11-23 | 2021-02-12 | 苏州大学 | 一种苯并噁唑-2-乙基肟衍生物、其制备方法及应用 |
| AU2020242287A1 (en) | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| TWI817018B (zh) | 2019-06-28 | 2023-10-01 | 美商艾瑞生藥股份有限公司 | 用於治療ｂｒａｆ相關的疾病和失調症之化合物 |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| US12303509B2 (en) | 2020-06-09 | 2025-05-20 | Pfizer Inc. | Compounds for the treatment of BRAF-associated diseases and disorders |
| WO2022251193A1 (en) | 2021-05-27 | 2022-12-01 | Mirati Therapeutics, Inc. | Combination therapies |
| WO2025073765A1 (en) | 2023-10-03 | 2025-04-10 | Institut National de la Santé et de la Recherche Médicale | Methods of prognosis and treatment of patients suffering from melanoma |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607683D0 (en) | 1986-03-27 | 1986-04-30 | Ici Plc | Anti-tumor agents |
| GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
| WO1993004063A1 (fr) | 1991-08-22 | 1993-03-04 | Yoshitomi Pharmaceutical Industries, Ltd. | Compose de benzisoxazole et son utilisation |
| US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| US5750545A (en) | 1993-07-23 | 1998-05-12 | The Green Cross Corporation | Triazole derivative and pharmaceutical use thereof |
| US5525625A (en) * | 1995-01-24 | 1996-06-11 | Warner-Lambert Company | 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders |
| US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
| CA2218503C (en) | 1995-04-20 | 2001-07-24 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives |
| DE19517448A1 (de) * | 1995-05-12 | 1996-11-14 | Thomae Gmbh Dr K | Neue Benzothiazole und Benzoxazole, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zu ihrer Herstellung |
| JP3195756B2 (ja) | 1996-07-04 | 2001-08-06 | 公子 吉水 | 潤滑補助体 |
| KR20000067904A (ko) | 1996-07-18 | 2000-11-25 | 디. 제이. 우드, 스피겔 알렌 제이 | 매트릭스 메탈로프로테아제의 포스피네이트계 억제제 |
| BR9711223A (pt) | 1996-08-23 | 1999-08-17 | Pfizer | Derivados de cido arilsulfonilamino-hidrox mico |
| EP0950059B1 (en) | 1997-01-06 | 2004-08-04 | Pfizer Inc. | Cyclic sulfone derivatives |
| IL131042A0 (en) | 1997-02-03 | 2001-01-28 | Pfizer Prod Inc | Arylsulfonylamino hydroxamic acid derivatives |
| BR9807824A (pt) | 1997-02-07 | 2000-03-08 | Pfizer | Derivados de n-hidróxi-beta-sulfonil-propionamida e seu uso como inibidores de metaloproteinases de matriz |
| KR20000070923A (ko) | 1997-02-11 | 2000-11-25 | 디. 제이. 우드, 스피겔 알렌 제이 | 아릴설포닐 하이드록삼산 유도체 |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| US6506798B1 (en) * | 1997-07-01 | 2003-01-14 | Warner-Lambert Company | 4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors |
| JP2002511092A (ja) | 1997-07-01 | 2002-04-09 | ワーナー−ランバート・コンパニー | ４−ブロモまたは４−ヨードフェニルアミノベンズヒドロキサム酸誘導体およびそのｍｅｋ阻害剤としての使用 |
| US6821963B2 (en) | 1997-07-01 | 2004-11-23 | Warner-Lambert Company | 4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors |
| US6310060B1 (en) | 1998-06-24 | 2001-10-30 | Warner-Lambert Company | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors |
| JP2002509536A (ja) | 1997-07-01 | 2002-03-26 | ワーナー−ランバート・カンパニー | ２−（４−ブロモ又は４−ヨードフェニルアミノ）安息香酸誘導体及びｍｅｋ阻害物質としてのそれらの使用 |
| US5877309A (en) * | 1997-08-13 | 1999-03-02 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides against JNK |
| GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
| GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
| PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
| PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
| CA2350234A1 (en) | 1999-01-07 | 2000-07-13 | Alexander James Bridges | Treatment of asthma with mek inhibitors |
| EP1140067A1 (en) | 1999-01-07 | 2001-10-10 | Warner-Lambert Company | Antiviral method using mek inhibitors |
| CA2348236A1 (en) | 1999-01-13 | 2000-07-20 | Stephen Douglas Barrett | 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors |
| JP2000204079A (ja) * | 1999-01-13 | 2000-07-25 | Warner Lambert Co | ジアリ―ルアミン |
| BR9916857A (pt) | 1999-01-13 | 2001-12-04 | Warner Lambert Co | 4 heteroaril diarilaminas |
| AP2001002225A0 (en) | 1999-01-13 | 2001-09-30 | Warner Lambert Co | 1-heterocycle substituted diarylamines. |
| IL144214A0 (en) * | 1999-01-13 | 2002-05-23 | Warner Lambert Co | Benzoheterocycles and their use as mek inhibitors |
| EP1144371B1 (en) | 1999-01-13 | 2005-11-09 | Warner-Lambert Company Llc | Benzenesulphonamide derivatives and their use as mek inhibitors |
| ATE311363T1 (de) | 1999-01-13 | 2005-12-15 | Warner Lambert Co | Sulfohydroxamsäure and sulfohydroxamate und ihre verwendung als mek-inhibitoren |
| GB9910577D0 (en) | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
| JP2003504401A (ja) | 1999-07-16 | 2003-02-04 | ワーナー−ランバート・カンパニー | Ｍｅｋ阻害剤を用いる慢性疼痛の治療方法 |
| CN1358094A (zh) | 1999-07-16 | 2002-07-10 | 沃尼尔·朗伯公司 | 用mek抑制剂治疗慢性疼痛的方法 |
| AU5786000A (en) | 1999-07-16 | 2001-02-05 | Warner-Lambert Company | Method for treating chronic pain using mek inhibitors |
| US7030119B1 (en) * | 1999-07-16 | 2006-04-18 | Warner-Lambert Company | Method for treating chronic pain using MEK inhibitors |
| HUP0202381A3 (en) | 1999-07-16 | 2004-12-28 | Warner Lambert Co | Method for treating chronic pain using mek inhibitors |
| BR0109188A (pt) | 2000-03-15 | 2003-03-18 | Warner Lambert Co | Diarilaminas 5-amida substituìdas como inibidores de mex |
| IL153817A0 (en) | 2000-07-19 | 2003-07-31 | Warner Lambert Co | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids |
| MXPA03001654A (es) | 2000-08-25 | 2004-09-10 | Warner Lambert Co | Proceso para la elaboracion del acido n-aril-antranilico y sus derivados. |
| US20020052373A1 (en) * | 2000-10-26 | 2002-05-02 | Zorn Stevin H. | Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease |
| AU2002210714A1 (en) | 2000-11-02 | 2002-06-11 | Astrazeneca Ab | Substituted quinolines as antitumor agents |
| US6748692B2 (en) * | 2001-10-23 | 2004-06-15 | Travis Sprouse | Spinner bait |
| US7235537B2 (en) * | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
| CA2478374C (en) * | 2002-03-13 | 2009-01-06 | Eli M. Wallace | N3 alkylated benzimidazole derivatives as mek inhibitors |
| CA2478534A1 (en) | 2002-03-13 | 2003-09-25 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as mek inhibitors |
| US20050049276A1 (en) * | 2003-07-23 | 2005-03-03 | Warner-Lambert Company, Llc | Imidazopyridines and triazolopyridines |
| US7144907B2 (en) * | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
-
2003
- 2003-09-03 US US10/654,580 patent/US7144907B2/en not_active Expired - Fee Related
-
2004
- 2004-08-30 US US10/929,295 patent/US7230099B2/en not_active Expired - Fee Related
- 2004-09-01 RU RU2006109599/04A patent/RU2006109599A/ru not_active Application Discontinuation
- 2004-09-01 KR KR1020067004505A patent/KR20060070558A/ko not_active Withdrawn
- 2004-09-01 ZA ZA200602581A patent/ZA200602581B/en unknown
- 2004-09-01 JP JP2006525449A patent/JP4131741B2/ja not_active Expired - Fee Related
- 2004-09-01 CA CA002537321A patent/CA2537321A1/en not_active Abandoned
- 2004-09-01 CN CNA2004800326551A patent/CN1874769A/zh active Pending
- 2004-09-01 MX MXPA06002466A patent/MXPA06002466A/es not_active Application Discontinuation
- 2004-09-01 AU AU2004270699A patent/AU2004270699B2/en not_active Ceased
- 2004-09-01 BR BRPI0414111-3A patent/BRPI0414111A/pt not_active IP Right Cessation
- 2004-09-01 EP EP04783028.6A patent/EP1673339B1/en not_active Expired - Lifetime
- 2004-09-01 WO PCT/US2004/028649 patent/WO2005023759A2/en not_active Ceased
- 2004-09-01 PT PT47830286T patent/PT1673339E/pt unknown
- 2004-09-02 TW TW093126520A patent/TW200526607A/zh unknown
- 2004-09-02 AR ARP040103151A patent/AR046081A1/es not_active Application Discontinuation
-
2006
- 2006-02-26 IL IL173936A patent/IL173936A/en not_active IP Right Cessation
- 2006-03-31 IS IS8392A patent/IS8392A/is unknown
- 2006-04-03 NO NO20061506A patent/NO20061506L/no not_active Application Discontinuation
- 2006-04-24 US US11/410,343 patent/US7271178B2/en not_active Expired - Fee Related
- 2006-04-24 US US11/410,344 patent/US20060189668A1/en not_active Abandoned
- 2006-04-24 US US11/410,336 patent/US7511058B2/en not_active Expired - Fee Related
-
2012
- 2012-05-08 IL IL219671A patent/IL219671A0/en unknown
- 2012-05-08 IL IL219670A patent/IL219670A/en not_active IP Right Cessation
- 2012-05-08 IL IL219669A patent/IL219669A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007504241A5 (OSRAM) | ||
| RU2006109599A (ru) | Гетероциклические ингибиторы мек и способы их применения | |
| AU2014219283C1 (en) | Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders | |
| ES2810852T3 (es) | Compuestos y composiciones para inhibir la actividad de shp2 | |
| RU2006120948A (ru) | Гетероциклические ингибиторы мек и способы их применения | |
| JP2004175807A5 (OSRAM) | ||
| TWI843372B (zh) | 用於降解突變kras蛋白之化合物及其應用 | |
| JP2007501779A5 (OSRAM) | ||
| JP2007511615A5 (OSRAM) | ||
| JP2013532652A5 (OSRAM) | ||
| EA030430B1 (ru) | Композиции и способы модуляции фарнезоидных х-рецепторов | |
| JP2008512490A5 (OSRAM) | ||
| RU2008110949A (ru) | Соединения и композиции-иммуносупрессанты | |
| JP2010513322A5 (OSRAM) | ||
| JP2017526677A5 (OSRAM) | ||
| JP2009524670A5 (OSRAM) | ||
| JP2009519243A5 (OSRAM) | ||
| JP2008509187A5 (OSRAM) | ||
| JP2014500322A5 (OSRAM) | ||
| JP2006523234A5 (OSRAM) | ||
| JP2011527345A5 (OSRAM) | ||
| CA3063804A1 (en) | A class of isoindolone-imide ring-1,3-dione-2-ene compounds, composition and use thereof | |
| JP2015503597A5 (OSRAM) | ||
| ES2548258T3 (es) | Compuestos de oxadiazol sustituidos y su uso como agonistas de S1P1 | |
| JP2022522312A (ja) | ピロール化合物 |